Can You Be Assessed for BNCT After 70 Gy of Head and Neck Radiotherapy?

Short answer

Yes, further assessment may be reasonable. However, a prior prescription of 70 Gy neither automatically excludes a patient from BNCT nor proves eligibility. In Japan, the approved indication covers unresectable locally advanced or locally recurrent head and neck cancer using borofalan (10B) with an approved neutron irradiation system. The treating center must still review the recurrent tumor, prior dose distribution, nearby critical structures, general condition, and available standard treatments.

Why 70 Gy is not a simple cutoff

“I already received 70 Gy” is an important fact, but it is not a complete radiation history. The prescription dose does not show how much radiation each normal structure received, how the original field overlaps the recurrence, or whether anatomy has changed after surgery and treatment.

BNCT is still a form of radiation therapy. A boron-containing drug is administered before neutron irradiation; the nuclear reaction occurs where boron-10 is present. This different mechanism does not remove the need to evaluate cumulative exposure and normal-tissue risk.

The current Japanese prescribing information does not use prior 70 Gy as a universal inclusion or exclusion threshold. It states that standard options such as chemoradiotherapy should be prioritized when feasible and that patient selection must be based on a full understanding of the available efficacy and safety evidence.

What a Japanese specialist usually needs to reassess

1. Confirmation of recurrence. Pathology, contrast-enhanced CT or MRI, PET when relevant, and treatment-related changes need to be interpreted together.
2. The original radiotherapy plan. Planning CT, DICOM-RT files, dose distributions, dose-volume histograms, and the treatment summary are more informative than the single number “70 Gy.” International reirradiation guidance supports using complete prior DICOM data when dose overlap or toxicity is a concern.
3. Tumor geometry. Size, depth, number of lesions, and proximity to the carotid artery, airway, brain, eye, spinal cord, and jaw can affect feasibility.
4. Other standard options. Salvage surgery, conventional or highly conformal reirradiation, systemic treatment, and multidisciplinary combinations should be compared first.
5. Overall disease and treatment goals. If widespread distant progression is the dominant problem, a local treatment may not be the immediate priority.

When an assessment may be relevant

• The disease is locally advanced or locally recurrent and has been considered unresectable.
• Different teams disagree about whether another local treatment is possible after prior radiotherapy.
• The recurrence is a major clinical problem and the patient wants a structured comparison of BNCT, other reirradiation approaches, and systemic therapy.
• Original imaging and radiation-planning data can be made available for review.

These points justify a review; they do not establish treatment eligibility.

When BNCT may not be appropriate, or another problem comes first

If a reasonable standard treatment remains available, it should be discussed before BNCT. The Japanese label contraindicates treatment when the tumor completely encases the carotid artery and warns of carotid bleeding when the artery is invaded. Emergency symptoms such as major bleeding, breathing difficulty, altered consciousness, severe infection, or rapid deterioration require urgent local care rather than a remote opinion.

Extensive distant progression, severe prior radiation injury, or an unacceptable risk to critical structures may also shift the decision away from local BNCT.

Records to prepare

• Pathology report, immunohistochemistry, and material suitable for pathology review if requested
• Recent contrast-enhanced CT or MRI, and PET when performed, including original DICOM files
• Planning CT, DICOM-RT, dose-volume histogram, field information, and treatment summary from every radiation course
• A dated timeline of surgery, systemic therapy, radiation, response, and recurrence
• Current symptoms, performance status, kidney function, and medicines
• Three to five questions that the patient wants the specialist to answer

Approved treatment versus research

Approved treatment in Japan: borofalan (10B) used with an approved BNCT system for unresectable locally advanced or locally recurrent head and neck cancer. Clinical use began in 2020. The regulatory evidence included JHN002, a small, open-label phase II study in a defined patient population. Group outcomes cannot predict an individual result.

Clinical trials or other research: BNCT for cancers or uses outside the Japanese label must be identified according to its actual status. The fact that a treatment shares the name “BNCT” does not make every application routine approved care.

FAQ

Does 70 Gy mean the body has reached a lifetime radiation limit?

No single prescription number defines a universal whole-body limit. Specialists need organ-specific prior doses, overlap, time interval, current anatomy, and previous toxicity.

Why might BNCT still be discussed after 70 Gy?

Its dose-delivery mechanism differs from conventional external-beam radiotherapy. Nevertheless, normal tissues are still exposed, so cumulative dose and anatomy remain central to safety assessment.

Can a patient with distant metastases be assessed?

The question can be reviewed, but the value of local treatment depends on systemic disease burden, symptoms, goals, and systemic-treatment options.

Will a second opinion recommend BNCT?

Not necessarily. It may support the current plan, request missing information, favor surgery or another radiation approach, or conclude that BNCT is not appropriate.

Does a written opinion require travel to Japan?

No. It can first be discussed with the treating team at home. Travel becomes relevant only if an in-person examination or treatment evaluation is needed.

Next step

Start with the second-opinion records checklist. Confirm whether pathology, recent original imaging, and the complete prior radiotherapy plan are available before deciding whether a written Japan Expert Second Opinion would add value. Do not post medical records or identity documents in public comments.

Risk notice

This article is for medical education and decision support. It is not a diagnosis, prescription, eligibility decision, or guarantee of benefit. Important risks in the Japanese prescribing information include swallowing disorders, severe skin injury, carotid bleeding, pharyngeal or laryngeal edema, and necrosis, ulceration, perforation, or fistula at the irradiated site. Individual risk must be assessed by an experienced head-and-neck cancer and BNCT team.

Primary sources

1. PMDA: Steboronine prescribing information, revision 6, April 2026
2. PMDA: Steboronine approval review information
3. Hirose et al.: JHN002 open-label phase II trial
4. ESTRO Reirradiation Focus Group: consensus guidance on cumulative dose evaluation

A second opinion is a decision-support tool. It may confirm the existing plan and does not automatically require travel to Japan.